Motesin (Azelastine Hydrochloride, Fluticasone Propionate)

Azelastine hydrochloride and fluticasone propionate, the active ingredients in Motesin, are an antihistamine and corticosteroid presented as a nasal spray for nasal use. They treat allergic rhinitis, including seasonal and perennial forms, by reducing histamine‑mediated symptoms and nasal inflammation.

GNH USA supplies Motesin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Motesin combines an antihistamine and a corticosteroid to address conditions within the allergic rhinitis disease family.

Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhea. Seasonal allergic rhinitis: provides relief of symptoms triggered by pollen or other seasonal allergens. Perennial allergic rhinitis: controls year‑round nasal inflammation and symptom recurrence.

Common Side Effects: - Nasal irritation or burning sensation - Headache - Bitter or unpleasant taste - Epistaxis (nosebleeds) - Throat irritation - Cough

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Vision changes or cataract formation - Adrenal suppression with prolonged use - Fungal infection of the nasal passages - Increased intraocular pressure or glaucoma

Before using Motesin, consider the following precautions. - Hypersensitivity: avoid if the patient has known allergy to azelastine, fluticasone, or any excipients. - Recent nasal surgery or trauma: use with caution and under medical supervision. - Nasal bleeding: monitor for persistent epistaxis and seek evaluation if it occurs. - Pediatric use: restrict to age groups recommended by the prescriber. - Systemic corticosteroid exposure: assess total steroid load if used with other steroid products. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Motesin may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) that may raise fluticasone systemic levels. - Concurrent intranasal corticosteroids, increasing risk of systemic glucocorticoid effects. - MAO inhibitors combined with azelastine, potentially enhancing antihistaminic effects.

Moderate Interactions (Monitor Closely):\n- Ritonavir or other potent CYP3A4 modulators, requiring clinical observation. - Oral corticosteroids, which may add to overall steroid exposure. - Other nasal decongestants, which can predispose to rebound congestion if used together.